Injectable Polypeptide Hydrogel Depots Containing Dual Immune Checkpoint Inhibitors and Doxorubicin for Improved Tumor Immunotherapy and Post-Surgical Tumor Treatment

Bibliographic Details
Title: Injectable Polypeptide Hydrogel Depots Containing Dual Immune Checkpoint Inhibitors and Doxorubicin for Improved Tumor Immunotherapy and Post-Surgical Tumor Treatment
Authors: Zhixiong Chen, Yan Rong, Junfeng Ding, Xueliang Cheng, Xuesi Chen, Chaoliang He
Source: Pharmaceutics, Vol 15, Iss 2, p 428 (2023)
Publisher Information: MDPI AG, 2023.
Publication Year: 2023
Collection: LCC:Pharmacy and materia medica
Subject Terms: hydrogel, combination therapy, immunotherapy, polypeptide, ICB therapy, Pharmacy and materia medica, RS1-441
More Details: In this work, we developed a strategy for local chemo-immunotherapy through simultaneous incorporation of dual immune checkpoint blockade (ICB) antibodies, anti-cytotoxic T-lymphocyte-associated protein 4 (aCTLA-4) and anti-programmed cell death protein 1 (aPD-1), and a chemotherapy drug, doxorubicin (Dox), into a thermo-gelling polypeptide hydrogel. The hydrogel encapsulating Dox or IgG model antibody showed sustained release profiles for more than 12 days in vitro, and the drug release and hydrogel degradation were accelerated in the presence of enzymes. In comparison to free drug solutions or hydrogels containing Dox or antibodies only, the Dox/aCTLA-4/aPD-1 co-loaded hydrogel achieved improved tumor suppression efficiency, strengthened antitumor immune response, and prolonged animal survival time after peritumoral injection into mice bearing B16F10 melanoma. Additionally, after injection of Dox/aCTLA-4/aPD-1 co-loaded hydrogel into the surgical site following tumor resection, a significantly enhanced inhibition on tumor reoccurrence was demonstrated. Thus, the polypeptide hydrogel-based chemo-immunotherapy strategy has potential in anti-tumor therapy and the prevention of tumor reoccurrence.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 15020428
1999-4923
Relation: https://www.mdpi.com/1999-4923/15/2/428; https://doaj.org/toc/1999-4923
DOI: 10.3390/pharmaceutics15020428
Access URL: https://doaj.org/article/ed4a2ec7fd224e01bfe7dc85a0bf37ab
Accession Number: edsdoj.4a2ec7fd224e01bfe7dc85a0bf37ab
Database: Directory of Open Access Journals
Full text is not displayed to guests.
More Details
ISSN:15020428
19994923
DOI:10.3390/pharmaceutics15020428
Published in:Pharmaceutics
Language:English